​

Biogen (BIIB) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

BIIB Stock Forecast

Biogen stock forecast is as follows: an average price target of $251.82 (represents a 71.93% upside from BIIB’s last price of $146.47) and a rating consensus of 'Buy', based on 33 wall street analysts offering a 1-year stock forecast.

BIIB Price Target

The average price target for Biogen (BIIB) is $251.82 based on 1-year price targets from 33 Wall Street analysts in the past 3 months, with a price target range of $315.00 to $180.00. This represents a potential 71.93% upside from BIIB's last price of $146.47.

BIIB Analyst Ratings

Buy

According to 33 Wall Street analysts, Biogen's rating consensus is 'Buy'. The analyst rating breakdown for BIIB stock is 0 'Strong Buy' (0.00%), 23 'Buy' (69.70%), 10 'Hold' (30.30%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Biogen Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 09, 2024Michael YeeJefferies$180.00$157.7814.08%22.89%
Nov 15, 2024Brian SkorneyRobert W. Baird$300.00$162.8384.24%104.82%
Oct 31, 2024Jay OlsonOppenheimer$255.00$181.1840.74%74.10%
Oct 31, 2024Terence FlynnMorgan Stanley$204.00$181.1812.60%39.28%
Oct 30, 2024Christopher RaymondRaymond James$315.00$181.1873.86%115.06%
Oct 30, 2024Salveen RichterGoldman Sachs$290.00$181.1860.06%97.99%
Oct 17, 2024Evan SeigermanBMO Capital$230.00$188.1622.23%57.03%
Oct 03, 2024Ashwani VermaUBS$202.00$188.747.03%37.91%
Sep 23, 2024Laura ChicoWedbush$205.00$199.362.83%39.96%
Jul 29, 2024Brian SkorneyRobert W. Baird$294.00$212.7038.22%100.72%
Jul 26, 2024Salveen RichterGoldman Sachs$342.00$211.1761.95%133.49%
Jul 26, 2024Christopher RaymondPiper Sandler$307.00$211.1745.38%109.60%
Jul 26, 2024Brian AbrahamsRBC Capital$282.00$214.1631.68%92.53%
Jul 12, 2024Christopher RaymondPiper Sandler$313.00$236.8032.18%113.70%
Jul 11, 2024Terence FlynnMorgan Stanley$311.00$232.7533.62%112.33%
Jun 12, 2024George FarmerScotiabank$275.00$230.2819.42%87.75%
May 23, 2024Evan David SeigermanBMO Capital$260.00$220.0018.18%77.51%
May 22, 2024Paul MatteisStifel Nicolaus$275.00$225.2122.11%87.75%
May 22, 2024Christopher RaymondRaymond James$335.00$225.2148.75%128.72%
May 22, 2024Matthew HarrisonMorgan Stanley$331.00$224.4847.45%125.98%
Apr 25, 2024Laura ChicoWedbush$215.00$204.655.06%46.79%
Apr 25, 2024Andrew FeinH.C. Wainwright$300.00$201.9948.52%104.82%
Apr 25, 2024Brian AbrahamsRBC Capital$317.00$201.9956.94%116.43%
Apr 19, 2024Jay OlsonOppenheimer$270.00$190.5241.72%84.34%
Apr 03, 2024Carter GouldBarclays$215.00$206.384.18%46.79%
Aug 07, 2023Laura ChicoWedbush$269.00$271.23-0.82%83.66%
May 01, 2023Yatin SunejaGuggenheim$350.00$311.1112.50%138.96%
Dec 01, 2022Atlantic Equities$295.00$305.17-3.33%101.41%
Nov 30, 2022Jefferies$350.00$308.4413.47%138.96%
Nov 30, 2022Wedbush$247.00$302.84-18.44%68.64%
Nov 30, 2022Barclays$313.00$291.417.41%113.70%
Nov 15, 2022Truist Financial$350.00$301.8615.95%138.96%
Nov 11, 2022Guggenheim$270.00$286.86-5.88%84.34%
Sep 30, 2022J.P. Morgan$275.00$264.284.06%87.75%
Sep 28, 2022Steve ChesneyAtlantic Equities$200.00$271.17-26.24%36.55%
Sep 28, 2022Ami FadiaNeedham$250.00$271.17-7.81%70.68%
Sep 28, 2022Matthew HarrisonMorgan Stanley$285.00$271.135.11%94.58%
Sep 28, 2022Wedbush$217.00$277.58-21.82%48.15%
Sep 28, 2022Wells Fargo$350.00$270.2929.49%138.96%
Sep 28, 2022RBC Capital$321.00$275.8816.36%119.16%
Sep 28, 2022Piper Sandler$280.00$197.7941.56%91.17%
Sep 28, 2022Evan David SeigermanBMO Capital$360.00$197.7982.01%145.78%
Sep 28, 2022Salim SyedMizuho Securities$270.00$197.7936.51%84.34%
Sep 28, 2022Brian SkorneyRobert W. Baird$340.00$197.7971.90%132.13%
Sep 28, 2022Ami FadiaNeedham$250.00$197.7926.40%70.68%
Sep 22, 2022Truist Financial$265.00$195.9235.26%80.92%
Sep 12, 2022Stifel Nicolaus$223.00$215.383.54%52.25%
Jul 21, 2022Cowen & Co.$270.00$214.1026.11%84.34%
Jul 21, 2022Truist Financial$270.00$213.1526.67%84.34%
Jul 21, 2022Barclays$200.00$212.95-6.08%36.55%
Jul 18, 2022Oppenheimer$230.00$216.686.15%57.03%
May 04, 2022Barclays$210.00$205.702.09%43.37%
Apr 21, 2022Leerink Partners$270.00$221.3621.97%84.34%
Apr 18, 2022Mohit BansalWells Fargo$265.00$212.5524.68%80.92%
Apr 16, 2022Carter GouldBarclays$219.00$212.553.03%49.52%
Apr 11, 2022Ami FadiaNeedham$262.00$210.6224.39%78.88%
Apr 09, 2022Laura ChicoWedbush$185.00$214.75-13.85%26.31%
Apr 07, 2022Brian SkorneyRobert W. Baird$224.00$211.645.84%52.93%
Apr 07, 2022Michael YeeJefferies$300.00$211.6441.75%104.82%
Apr 07, 2022Christopher RaymondPiper Sandler$200.00$211.64-5.50%36.55%
Apr 05, 2022Brian AbrahamsRBC Capital$244.00$207.6117.53%66.59%
Mar 28, 2022Geoff MeachamBank of America Securities$225.00$211.686.29%53.62%
Mar 15, 2022Evan SeigermanBMO Capital$238.00$197.3620.59%62.49%
Feb 28, 2022Sumant KulkarniCanaccord Genuity$285.00$211.0135.06%94.58%
Feb 22, 2022Yatin SunejaGuggenheim$200.00$209.81-4.68%36.55%
Feb 16, 2022Robyn KarnauskasTruist Financial$320.00$214.5549.15%118.47%
Feb 13, 2022Ami FadiaNeedham$290.00$214.5935.14%97.99%
Feb 07, 2022Salim SyedMizuho Securities$207.00$221.30-6.46%41.33%
Feb 04, 2022Carter GouldBarclays$235.00$221.536.08%60.44%
Feb 04, 2022Mohit BansalWells Fargo$235.00$221.536.08%60.44%
Feb 04, 2022Tim AndersonWolfe Research$217.00$221.53-2.04%48.15%
Feb 04, 2022Matthew HarrisonMorgan Stanley$330.00$221.5348.96%125.30%
Feb 04, 2022Phil NadeauCowen & Co.$285.00$221.5328.65%94.58%
Feb 03, 2022Cory KasimovJ.P. Morgan$236.00$220.177.19%61.13%
Jan 30, 2022Ami FadiaNeedham$292.00$225.2129.66%99.36%
Jan 16, 2022Michael YeeJefferies$325.00$239.3035.81%121.89%
Jan 12, 2022Alethia YoungCantor Fitzgerald$209.00$225.34-7.25%42.69%
Jan 03, 2022Aaron GalBernstein$400.00$244.1463.84%173.09%
Dec 06, 2021Salveen RichterGoldman Sachs$271.00$224.1120.92%85.02%
Oct 20, 2021Colin BristowUBS$405.00$266.5751.93%176.51%
Jun 08, 2021Steve ChesneyAtlantic Equities$415.00$395.374.96%183.33%

The latest Biogen stock forecast, released on Dec 09, 2024 by Michael Yee from Jefferies, set a price target of $180.00, which represents a 14.08% increase from the stock price at the time of the forecast ($157.78), and a 22.89% increase from BIIB last price ($146.47).

Biogen Price Target by Period

1M3M12M
# Anlaysts1925
Avg Price Target$180.00$242.33$272.92
Last Closing Price$146.47$146.47$146.47
Upside/Downside22.89%65.45%86.33%

In the current month, the average price target of Biogen stock is $180.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 22.89% increase as opposed to Biogen's last price of $146.47. This month's average price target is down -25.72% compared to last quarter, and down -34.05% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Dec 09, 2024JefferiesBuyHoldDowngrade
Nov 13, 2024CitigroupNeutralNeutralInitialise
Oct 31, 2024OppenheimerOutperformOutperformHold
Oct 31, 2024Morgan StanleyOverweightEqual-WeightDowngrade
Oct 30, 2024Piper SandlerOverweightOverweightHold
Oct 30, 2024Goldman SachsBuyBuyHold
Oct 17, 2024BMO CapitalOutperformOutperformHold
Oct 03, 2024UBSNeutralNeutralHold
Sep 24, 2024Cowen & Co.BuyBuyHold
Sep 23, 2024Wells FargoBuyBuyHold
Sep 23, 2024WedbushUnderperformUnderperformHold
Sep 23, 2024WedbushNeutralNeutralHold
Sep 05, 2024BMO CapitalOutperformOutperformHold
Aug 19, 2024Wells FargoBuyBuyHold
Jul 26, 2024Goldman SachsBuyBuyHold
Jul 26, 2024RBC CapitalOutperformOutperformHold
Jul 12, 2024Piper SandlerOverweightOverweightHold
Jul 11, 2024Morgan StanleyOverweightOverweightHold
Jul 03, 2024William BlairOutperformOutperformHold
Jun 26, 2024RBC CapitalOutperformOutperformHold
Jun 26, 2024WedbushBuyBuyHold
Jun 12, 2024ScotiabankSector OutperformSector OutperformHold
May 29, 2024RBC CapitalOutperformOutperformHold
May 23, 2024BMO CapitalOutperformOutperformHold
May 22, 2024WedbushBuyBuyHold
May 22, 2024Piper SandlerOverweightOverweightHold
May 22, 2024Morgan StanleyOverweightOverweightHold
May 03, 2024HSBCBuyBuyHold
Apr 25, 2024WedbushNeutralNeutralHold
Apr 25, 2024H.C. WainwrightBuyBuyHold
Apr 25, 2024RBC CapitalOutperformOutperformHold
Apr 19, 2024OppenheimerOutperformOutperformHold
Apr 11, 2024Wells FargoBuyBuyHold
Mar 05, 2024Wells FargoBuyBuyHold
Feb 14, 2024NeedhamBuyBuyHold
Feb 13, 2024UBSBuyBuyHold
Jan 24, 2024Wells FargoBuyBuyHold
Dec 07, 2023Raymond JamesOutperformUpgrade
May 01, 2023GuggenheimNeutralBuyUpgrade
Apr 17, 2023Piper SandlerNeutralOverweightUpgrade
Feb 06, 2023RBC CapitalSector PerformSector PerformHold
Feb 03, 2023SVB LeerinkOutperformOutperformHold
Jan 06, 2023Piper SandlerNeutralNeutralHold
Dec 01, 2022Atlantic EquitiesNeutralNeutralHold
Nov 30, 2022JefferiesBuyBuyHold
Nov 30, 2022WedbushNeutralNeutralHold
Nov 30, 2022BarclaysEqual-WeightEqual-WeightHold
Nov 14, 2022OppenheimerOutperformOutperformHold
Nov 11, 2022GuggenheimNeutralNeutralHold
Oct 26, 2022Fox AdvisorsEqual-WeightDowngrade
Oct 26, 2022Craig-HallumBuyUpgrade
Oct 26, 2022Goldman SachsNeutralDowngrade
Oct 26, 2022BTIGBuyUpgrade
Oct 26, 2022Deutsche BankBuyUpgrade
Oct 26, 2022Credit SuisseUnderperformDowngrade
Oct 26, 2022Hovde GroupMarket PerformDowngrade
Oct 25, 2022Piper SandlerNeutralNeutralHold
Oct 18, 2022JefferiesPositivePositiveHold
Oct 13, 2022Stifel NicolausBuyUpgrade
Oct 07, 2022CitigroupNeutralDowngrade
Oct 07, 2022RBC CapitalOutperformSector PerformDowngrade
Oct 07, 2022Cantor FitzgeraldNeutralDowngrade
Oct 07, 2022William BlairMarket PerformDowngrade
Oct 07, 2022Keefe, Bruyette & WoodsMarket PerformDowngrade
Oct 07, 2022Argus ResearchBuyUpgrade
Sep 28, 2022Atlantic EquitiesNeutralOverweightUpgrade
Sep 28, 2022New StreetOutperformUpgrade
Sep 28, 2022Evercore ISIOutperformUpgrade
Sep 28, 2022Bank of America SecuritiesOverweightOverweightHold
Sep 28, 2022Atlantic EquitiesNeutralNeutralHold
Sep 28, 2022Morgan StanleyOverweightOverweightHold
Sep 28, 2022WedbushNeutralNeutralHold
Sep 28, 2022Wells FargoOverweightOverweightHold
Sep 28, 2022RBC CapitalOutperformOutperformHold
Sep 28, 2022Piper SandlerNeutralNeutralHold
Sep 28, 2022BMO CapitalMarket PerformOutperformUpgrade
Sep 28, 2022Mizuho SecuritiesBuyUpgrade
Jul 21, 2022Cowen & Co.OutperformOutperformHold
Jul 21, 2022BarclaysEqual-WeightEqual-WeightHold
Jul 21, 2022NeedhamBuyBuyHold
Jul 18, 2022OppenheimerOutperformOutperformHold
Apr 18, 2022Wells FargoOverweightUpgrade
Apr 15, 2022BarclaysEqual-WeightEqual-WeightHold
Apr 11, 2022NeedhamBuyBuyHold
Apr 09, 2022WedbushNeutralNeutralHold
Feb 21, 2022BMO CapitalMarket PerformMarket PerformHold
Jan 30, 2022NeedhamBuyBuyHold
Jan 16, 2022JefferiesBuyBuyHold
Dec 27, 2021OppenheimerOutperformOutperformHold
Jun 07, 2021Piper SandlerNeutralNeutralHold
Nov 06, 2020SVB LeerinkOutperformOutperformHold

Biogen's last stock rating was published by Jefferies on Dec 09, 2024. The company Downgrade its BIIB rating from "Buy" to "Hold".

Biogen Financial Forecast

Biogen Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue-------------$2.53B$2.46B$2.46B$2.54B$2.51B$2.59B$2.53B$2.73B$2.78B$2.77B$2.69B$2.85B$3.38B$3.68B$3.53B$3.67B$3.60B
Avg Forecast$2.51B$2.47B$2.41B$2.34B$2.41B$2.39B$2.39B$2.33B$2.41B$2.43B$2.39B$2.31B$2.47B$2.40B$2.37B$2.34B$2.45B$2.47B$2.47B$2.50B$2.62B$2.67B$2.61B$2.65B$2.80B$3.33B$3.43B$3.42B$3.54B$3.54B
High Forecast$2.61B$2.57B$2.50B$2.42B$2.50B$2.47B$2.48B$2.45B$2.47B$2.44B$2.40B$2.31B$2.56B$2.51B$2.46B$2.43B$2.54B$2.47B$2.47B$2.50B$2.62B$2.67B$2.61B$2.65B$2.80B$3.33B$3.43B$3.42B$3.54B$3.54B
Low Forecast$2.41B$2.37B$2.31B$2.24B$2.32B$2.29B$2.29B$2.26B$2.24B$2.43B$2.39B$2.31B$2.35B$2.29B$2.27B$2.25B$2.35B$2.47B$2.47B$2.50B$2.62B$2.67B$2.61B$2.65B$2.80B$3.33B$3.43B$3.42B$3.54B$3.54B
# Analysts6446437925122522272613151412122425132313131599168
Surprise %-------------1.05%1.04%1.05%1.04%1.02%1.05%1.01%1.04%1.04%1.06%1.02%1.02%1.01%1.07%1.03%1.04%1.02%

Biogen's average Quarter revenue forecast for Dec 23 based on 27 analysts is $2.47B, with a low forecast of $2.35B, and a high forecast of $2.56B. BIIB's average Quarter revenue forecast represents a -2.54% decrease compared to the company's last Quarter revenue of $2.53B (Sep 23).

Biogen EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts6446437925122522272613151412122425132313131599168
EBITDA-------------$371.70M$708.60M$577.10M$515.10M$971.00M$1.04B$739.60M$1.01B$502.80M$168.70M$666.00M$517.60M$1.13B$2.17B$1.86B$1.87B$2.13B
Avg Forecast$936.89M$921.46M$899.01M$870.80M$899.19M$888.97M$891.28M$870.05M$899.94M$907.35M$891.66M$906.78M$919.08M$894.36M$882.12M$824.35M$1.11B$860.07M$861.72M$749.41M$912.66M$929.83M$908.92M$626.36M$974.21M$1.16B$1.19B$1.52B$1.23B$1.23B
High Forecast$972.16M$956.15M$932.85M$903.59M$933.05M$922.44M$924.83M$914.67M$922.35M$907.98M$892.96M$1.09B$952.71M$936.76M$915.34M$989.22M$1.33B$860.07M$861.72M$899.29M$912.66M$929.83M$908.92M$751.63M$974.21M$1.16B$1.19B$1.82B$1.23B$1.23B
Low Forecast$899.05M$884.25M$862.70M$835.64M$862.88M$853.07M$855.29M$844.02M$836.46M$906.72M$890.37M$725.43M$874.25M$852.15M$846.51M$659.48M$888.28M$860.07M$861.72M$599.53M$912.66M$929.83M$908.92M$501.09M$974.21M$1.16B$1.19B$1.21B$1.23B$1.23B
Surprise %-------------0.42%0.80%0.70%0.46%1.13%1.21%0.99%1.11%0.54%0.19%1.06%0.53%0.98%1.81%1.22%1.52%1.73%

27 analysts predict BIIB's average Quarter EBITDA for Dec 23 to be $919.08M, with a high of $952.71M and a low of $874.25M. This is 147.26% upper than Biogen's previous annual EBITDA (Sep 23) of $371.70M.

Biogen Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts6446437925122522272613151412122425132313131599168
Net Income-------------$-68.10M$591.60M$387.90M$550.40M$1.13B$1.06B$221.80M$-38.20M$329.20M$448.50M$410.20M$357.90M$701.50M$1.54B$1.40B$1.44B$1.55B
Avg Forecast$617.81M$481.09M$520.73M$486.66M$605.25M$605.93M$624.27M$581.06M$498.06M$550.39M$593.52M$431.38M$464.54M$579.74M$551.00M$392.17M$403.82M$601.96M$592.38M$356.51M$492.71M$596.18M$663.72M$385.78M$699.11M$1.18B$1.17B$1.14B$1.17B$1.21B
High Forecast$648.05M$504.64M$546.22M$510.48M$634.87M$635.59M$654.82M$631.33M$581.07M$550.87M$597.02M$517.66M$567.45M$653.84M$577.97M$470.60M$484.59M$601.96M$592.38M$427.82M$492.71M$596.18M$663.72M$462.94M$699.11M$1.18B$1.17B$1.37B$1.17B$1.21B
Low Forecast$585.38M$455.84M$493.40M$461.12M$573.48M$574.12M$591.50M$507.13M$474.76M$549.91M$590.02M$345.11M$404.27M$451.88M$522.07M$313.73M$323.06M$601.96M$592.38M$285.21M$492.71M$596.18M$663.72M$308.63M$699.11M$1.18B$1.17B$915.12M$1.17B$1.21B
Surprise %--------------0.12%1.07%0.99%1.36%1.89%1.79%0.62%-0.08%0.55%0.68%1.06%0.51%0.59%1.32%1.22%1.23%1.28%

Biogen's average Quarter net income forecast for Sep 23 is $579.74M, with a range of $451.88M to $653.84M. BIIB's average Quarter net income forecast represents a -2.01% decrease compared to the company's last Quarter net income of $591.60M (Jun 23).

Biogen SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts6446437925122522272613151412122425132313131599168
SG&A-------------$788.20M$548.00M$605.00M$632.80M$563.30M$572.60M$634.90M$787.90M$654.10M$637.30M$595.00M$806.20M$573.10M$555.10M$570.10M$664.90M$554.50M
Avg Forecast$548.23M$539.21M$526.07M$509.56M$526.18M$520.19M$521.54M$509.12M$526.61M$530.95M$521.77M$901.53M$537.81M$523.35M$516.19M$819.57M$864.13M$538.47M$539.51M$745.07M$571.40M$582.15M$569.06M$559.58M$609.94M$727.27M$748.03M$466.11M$771.61M$771.73M
High Forecast$568.87M$559.51M$545.87M$528.75M$545.99M$539.78M$541.18M$535.23M$539.72M$531.32M$522.53M$1.08B$557.49M$548.16M$535.62M$983.49M$1.04B$538.47M$539.51M$894.08M$571.40M$582.15M$569.06M$671.50M$609.94M$727.27M$748.03M$559.33M$771.61M$771.73M
Low Forecast$526.09M$517.43M$504.82M$488.99M$504.93M$499.19M$500.48M$493.89M$489.47M$530.58M$521.01M$721.22M$511.58M$498.64M$495.34M$655.66M$691.30M$538.47M$539.51M$596.05M$571.40M$582.15M$569.06M$447.67M$609.94M$727.27M$748.03M$372.89M$771.61M$771.73M
Surprise %-------------1.51%1.06%0.74%0.73%1.05%1.06%0.85%1.38%1.12%1.12%1.06%1.32%0.79%0.74%1.22%0.86%0.72%

Biogen's average Quarter SG&A projection for Dec 23 is $537.81M, based on 27 Wall Street analysts, with a range of $511.58M to $557.49M. The forecast indicates a -31.77% fall compared to BIIB last annual SG&A of $788.20M (Sep 23).

Biogen EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts6446437925122522272613151412122425132313131599168
EPS-------------$-0.47$4.09$2.69$3.82$7.86$7.25$1.51$-0.26$2.22$3.00$2.70$2.33$4.47$9.60$8.10$8.10$8.40
Avg Forecast$4.23$3.30$3.57$3.34$4.15$4.15$4.28$3.98$3.41$3.77$4.07$3.47$3.18$3.97$3.78$3.28$3.49$4.13$4.06$4.34$3.38$4.09$4.55$4.98$4.79$8.09$8.02$7.72$8.03$8.30
High Forecast$4.44$3.46$3.74$3.50$4.35$4.36$4.49$4.33$3.98$3.78$4.09$3.48$3.89$4.48$3.96$3.44$3.66$4.13$4.06$4.34$3.38$4.09$4.55$4.98$4.79$8.09$8.02$7.72$8.03$8.30
Low Forecast$4.01$3.12$3.38$3.16$3.93$3.94$4.05$3.48$3.25$3.77$4.04$3.46$2.77$3.10$3.58$3.11$3.31$4.13$4.06$4.34$3.38$4.09$4.55$4.98$4.79$8.09$8.02$7.72$8.03$8.30
Surprise %--------------0.12%1.08%0.82%1.09%1.91%1.79%0.35%-0.08%0.54%0.66%0.54%0.49%0.55%1.20%1.05%1.01%1.01%

According to 26 Wall Street analysts, Biogen's projected average Quarter EPS for Sep 23 is $3.97, with a low estimate of $3.10 and a high estimate of $4.48. This represents a -2.85% decrease compared to BIIB previous annual EPS of $4.09 (Jun 23).

Biogen Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
BIIBBiogen$150.64$251.8267.17%Buy
GSKGSK$34.23$53.0054.83%Hold
MRKMerck$100.06$135.8335.75%Buy
AMGNAmgen$265.95$338.2227.17%Buy
SNYSanofi$48.94$62.0026.69%Buy
PFEPfizer$26.43$32.8324.21%Hold
NVSNovartis$99.10$120.5021.59%Hold
ABBVAbbVie$175.38$211.2020.42%Buy
JNJJohnson & Johnson$146.41$175.1319.62%Buy
GILDGilead Sciences$92.80$87.30-5.93%Buy
BMYBristol-Myers Squibb Company$57.65$50.50-12.40%Hold

BIIB Forecast FAQ

Is Biogen a good buy?

Yes, according to 33 Wall Street analysts, Biogen (BIIB) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 23 'Buy' recommendations, accounting for 69.70% of BIIB's total ratings.

What is BIIB's price target?

Biogen (BIIB) average price target is $251.82 with a range of $180 to $315, implying a 71.93% from its last price of $146.47. The data is based on 33 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Biogen stock go up soon?

According to Wall Street analysts' prediction for BIIB stock, the company can go up by 71.93% (from the last price of $146.47 to the average price target of $251.82), up by 115.06% based on the highest stock price target, and up by 22.89% based on the lowest stock price target.

Can Biogen stock reach $200?

BIIB's average twelve months analyst stock price target of $251.82 supports the claim that Biogen can reach $200 in the near future.

What is Biogen's current price target trend?

1 Wall Street analyst forecast a $180 price target for Biogen (BIIB) this month, up 22.89% from its last price of $146.47. Compared to the last 3 and 12 months, the average price target increased by 65.45% and increased by 86.33%, respectively.

What are Biogen's analysts' financial forecasts?

Biogen's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $9.52B (high $9.91B, low $9.16B), average EBITDA is $3.55B (high $3.69B, low $3.42B), average net income is $2.42B (high $2.56B, low $2.25B), average SG&A $2.08B (high $2.16B, low $2B), and average EPS is $16.56 (high $17.52, low $15.4). BIIB's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $9.73B (high $10.1B, low $9.34B), average EBITDA is $3.63B (high $3.76B, low $3.48B), average net income is $2.11B (high $2.21B, low $2B), average SG&A $2.12B (high $2.2B, low $2.04B), and average EPS is $14.44 (high $15.14, low $13.68).

Did the BIIB's actual financial results beat the analysts' financial forecasts?

Based on Biogen's last annual report (Dec 2022), the company's revenue was $10.17B, beating the average analysts forecast of $9.89B by 2.89%. Apple's EBITDA was $2.69B, missing the average prediction of $3.58B by -25.00%. The company's net income was $3.05B, beating the average estimation of $1.95B by 55.88%. Apple's SG&A was $2.4B, missing the average forecast of $2.69B by -10.55%. Lastly, the company's EPS was $20.96, beating the average prediction of $16.02 by 30.88%. In terms of the last quarterly report (Sep 2023), Biogen's revenue was $2.53B, beating the average analysts' forecast of $2.4B by 5.44%. The company's EBITDA was $371.7M, missing the average prediction of $894.36M by -58.44%. Biogen's net income was $-68.1M, missing the average estimation of $579.74M by -111.75%. The company's SG&A was $788.2M, beating the average forecast of $523.35M by 50.61%. Lastly, the company's EPS was $-0.47, missing the average prediction of $3.97 by -111.83%